Dermatofibrosarcoma protuberans is a rare, low-grade malignant soft tissue sarcoma. Although its overall incidence rate is low and its survival rate is high, the incidence of this disease has increased gradually in recent years. The high recurrence rate of this disease can be attributed to the limited understanding of its pathogenesis and the restricted treatment options available. In recent years, as research on cancer pathogenesis has become more extensive, there has been a growing emphasis on immune-related issues that are closely associated with the occurrence and progression of cancer. This article provides an overview of current research on the immune response to dermatofibrosarcoma protuberans, including studies on tumour-related antigen expression, antigen-presenting cell expression, immune cell infiltration, and radiotherapy. By summarizing and analyzing the research findings, we aim to provide a valuable reference for understanding the pathogenesis of this disease from an immunological perspective and proposing novel treatment strategies.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: